Although trypanocidal therapy with benznidazole effectively cures the acute phase of Chagas disease, it did not significantly alter cardiac deterioration in Chagas cardiomyopathy in a trial conducted in Argentina, Bolivia, Brazil, Columbia, and El Salvador. Chagas disease ranks as the third most common parasitic disease globally, with approximately 25% of infected patients developing Chagas cardiomyopathy (Morillo CA et al. N Engl J Med. doi:10.1056/NEJMoa1507574 [published online September 1, 2015]).
Slomski A. Benznidazole Does Not Affect Chagas Cardiomyopathy. JAMA. 2015;314(16):1684. doi:10.1001/jama.2015.12704